On March 19, Teresa, Chief Operating Officer of ArbeleBio China, and Tony Wong, Head of R&D, visited Shenzhen Cell Valley for exchange. Our company's Chairman Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Chief Advisor Dr. David Jin, Deputy General Manager Tang Xiaomeng, R&D Department Head Zhao Lijun, and Marketing Department Head Yang Jianglong warmly received them.

Led by Wei Zheng, Assistant to the Chairman, the ArbeleBio experts visited the Smart Exhibition Hall, production workshops, and R&D laboratories, gaining a preliminary understanding of Shenzhen Cell Valley's development history, core technology patents, the role and advantages of retroviral vectors in cell therapy, and expressed high appreciation for Shenzhen Cell Valley's advanced technology and innovative strength.

During the symposium, Professor Shi Yuanyuan first extended a warm welcome to the ArbeleBio experts. Subsequently, both parties discussed recent corporate scientific research progress, cell therapy technologies, viral vector applications, market prospects, and project implementation plans.Professor Shi Yuanyuan provided a detailed introduction to Deep Harbour Cell Valley's core technology: the unique production process of retroviral vectors (such as the PackRV-SS system). He  explained how cell products including CAR-T, CAR-NK, and TCR-T can enable pharmaceutical companies to achieve low-cost, high-quality industrial production. He also highlighted significant breakthroughs in the culture expansion and transduction efficiency of CAR-NK and CAR-γδT cells, offering new possibilities for the treatment of solid tumors. Teresa introduced ArbeleBio's core proprietary technology platform centered on immunotherapy, and noted that Arbele's unique bispecific antibody innovative drugs have currently filed INDs in Hong Kong and Australia for the treatment of advanced gastrointestinal malignancies.

Teresa stated that ArbeleBio has always been committed to research and development in the biomedical field and hopes to collaborate with Shenzhen Cell Valley as soon as possible to conduct IIT clinical studies on solid tumors. Through this visit and exchange, both parties have laid a solid foundation for ArbeleBio's subsequent product development and market promotion.

Arbele (Arbele Ltd.) was established in 2016 as a biotechnology and biopharmaceutical company focused on inventing and developing breakthrough innovative immunotherapies, providing first-class cancer drugs and high-quality diagnostic screening platforms for early disease intervention. Arbele was founded by senior drug R&D experts and executives who previously worked at Johnson & Johnson, Roche, Sanofi, and Bristol-Myers Squibb. Its scientific team comes from Cambridge, Oxford, Harvard, and the University of Hong Kong. Headquartered in Hong Kong, it has research and business divisions in Guangzhou, Seattle, and Sydney, targeting high-mortality cancers such as gastric cancer, pancreatic cancer, colon cancer, bile duct cancer, and liver cancer, for which current treatment options are limited.